Research programme: cancer stem cell therapeutics - OncoCyte

Drug Profile

Research programme: cancer stem cell therapeutics - OncoCyte

Latest Information Update: 22 May 2015

Price : $50

At a glance

  • Originator OncoCyte Corporation
  • Class Stem cell therapies
  • Mechanism of Action Gene expression stimulants; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 22 May 2015 Preclinical development is ongoing in USA (Parenteral) (OncoCyte, website, May 2015)
  • 26 Jan 2015 OncoCyte Corporation receives patent allowance for applications of stem cells to cancer therapeutics in USA
  • 16 Oct 2009 Preclinical trials in Cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top